HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Paul Urbanski Gary L. Grunkemeier Robert W. Hacker Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, H.-H. Articles by Hacker, R. W. Search for Related Content PubMed PubMed Citation Articles by Li, H.-H. Articles by Hacker, R. W. Related Collections Valve disease Related Article

Ann Thorac Surg 2001;71:1181-1187
© 2001 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Intermediate-term results with 1,019 Carbomedics aortic valves

^a Herz- und Gefaessklinik, Bad Neustadt, Germany
^b Providence Health System, Portland, Oregon, USA

Accepted for publication September 15, 2000.

Address reprint requests to Dr Li, 9155 SW Barnes Rd, #33, Portland, OR 97225
e-mail: huihuali{at}msn.com

Background. A retrospective study was conducted to evaluate the intermediate-term outcome in patients with the Carbomedics aortic valve prosthesis.

Methods. The study included 1,019 primary valve replacements between 1989 and 1997. Seventy-two percent of patients were men; mean (standard deviation) age was 61 (10) years. The preoperative New York Heart Association functional class was III or IV in 70% of patients. Follow-up at 9 years was 99.6% complete, comprising 2,730 patient-years (mean, 2.7 years).

Results. Patient survival, including operative deaths, was 80% at 7 years. The linearized death rate was 2.9%/year. Statistically significant risk factors for mortality were diabetes, pure valve insufficiency, advanced age at operation, and advanced preoperative functional class. Linearized rates were thrombosis, 0.1%/year; thromboembolism, 1.0%/year; hemorrhage, 1.7%/year; endocarditis, 0.1%/year; paravalvular leak, 0.1%/year; reoperation, 0.1%/year; and all events, 3.0%/year. The 7-year estimates of freedom from complications were thrombosis, 99%; thromboembolism, 93%; hemorrhage, 89%; endocarditis, 99%; paravalvular leak, 99.7%; reoperation, 99%; and all events, 82%. No structural valve failure was observed.

Conclusions. The low incidence of valve-related complications favors the continued use of the Carbomedics valve in the aortic position.

Related Article

Invited commentary

Eric G. Butchart
Ann. Thorac. Surg. 2001 71: 1187-1188. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				J. M. Bernal, J. Lorca, D. Prieto-Salceda, I. Pulitani, A. Ponton, I. Garcia, and J. M. Revuelta Performance at 10 years of the CarboMedics 'Top-Hat' valve. Postclamping time is a predictor of mortality Eur. J. Cardiothorac. Surg., February 1, 2006; 29(2): 144 - 149. [Abstract] [Full Text] [PDF]

				A. M. Gillinov, E. H. Blackstone, J. M. Alster, J. M. Craver, W. A. Baumgartner, S. A. Brewster, L. H. Kleinman, and N. G. Smedira The Carbomedics Top Hat supraannular aortic valve: a multicenter study Ann. Thorac. Surg., April 1, 2003; 75(4): 1175 - 1180. [Abstract] [Full Text] [PDF]

				G. L. Grunkemeier and Y. Wu "Our complication rates are lower than theirs": Statistical critique of heart valve comparisons J. Thorac. Cardiovasc. Surg., February 1, 2003; 125(2): 290 - 300. [Abstract] [Full Text] [PDF]

				J.B. Borman and C. De Riberolles Sorin BicarbonTM bileaflet valve: a 10-year experience Eur. J. Cardiothorac. Surg., January 1, 2003; 23(1): 86 - 92. [Abstract] [Full Text] [PDF]